ArticleTranslational andrology and urology2026
A prediction model for targeted drug resistance in renal cell carcinoma based on plasma proteomics analysis.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Over the past decade, the prognosis of patients with metastatic renal cell carcinoma (mRCC) has significantly improved owing to the development of anti-angiogenic targeted drugs such as sunitinib, pazopanib, and sorafenib. However, biomarkers that can identify patients with mRCC who may rapidly develop drug resistance are still lacking. Approximately 25% of patients experience rapid disease progression [progression-free survival (PFS) ≤3 months]. Currently, there is a lack of effective noninvasive biomarkers to identify resistant patients prior to treatment. This study aimed to identify plasma biomarkers associated with therapeutic resistance and develop a predictive model for clinical decision-making. Methods: Plasma proteomic analysis was conducted in 159 patients with mRCC treated with targeted therapy. Patients were divided into training and validation cohorts. Candidate protein biomarkers were initially screened using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and further validated using enzyme-linked immunosorbent assay (ELISA). A predictive nomogram was subsequently developed using logistic regression analysis and assessed for discrimination and calibration performance. Immunohistochemistry (IHC) was performed to compare protein expression levels in corresponding tumor tissue samples. Results: Four plasma proteins-chitotriosidase-1 (CHIT1), interleukin-6 receptor (IL-6R), neuronal cell adhesion molecule (NRCAM), and ecto-5'-nucleotidase (NT5E)-were identified as significant predictors of intrinsic resistance. The nomogram incorporating these biomarkers exhibited a high predictive accuracy, with a concordance index (C-index) of 0.956 and 0.869 for the training and validation cohorts, respectively. Notably, while the plasma concentrations of these proteins were significantly elevated in resistant patients, their expression levels in tumor tissues showed no significant differences, underscoring their utility as circulating, noninvasive biomarkers. Conclusions: We developed and validated a plasma protein-based nomogram to predict mRCC resistance to targeted therapy. The four identified biomarkers allow noninvasive identification of high-risk patients and offer a practical tool for early clinical stratification. This model may assist clinicians in avoiding ineffective treatment and optimizing therapeutic strategies for patients with mRCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.